Published in Am J Geriatr Pharmacother on August 01, 2010
Brain networks in Huntington disease. J Clin Invest (2011) 1.02
Transforming Growth Factor-Beta Signaling in the Neural Stem Cell Niche: A Therapeutic Target for Huntington's Disease. Neurol Res Int (2011) 0.92
Effect of tetrabenazine on computerized dynamic posturography in Huntington disease patients. Parkinsonism Relat Disord (2012) 0.85
The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem Int (2014) 0.84
New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Devel Ther (2013) 0.84
Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression. J Neurosci (2013) 0.82
Promise of pharmacogenomics for drug discovery, treatment and prevention of Parkinson's disease. A perspective. Neurotherapeutics (2014) 0.79
Fluoxetine Administration Exacerbates Oral Tremor and Striatal Dopamine Depletion in a Rodent Pharmacological Model of Parkinsonism. Neuropsychopharmacology (2015) 0.78
The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion. Psychopharmacology (Berl) (2014) 0.78
Management of Huntington's disease: role of tetrabenazine. Ther Clin Risk Manag (2011) 0.78
The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs. PLoS One (2014) 0.78
Selection of sucrose concentration depends on the effort required to obtain it: studies using tetrabenazine, D1, D2, and D3 receptor antagonists. Psychopharmacology (Berl) (2015) 0.78
Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease. Drugs (2016) 0.78
DNA methylation in Huntington's disease: Implications for transgenerational effects. Neurosci Lett (2015) 0.77
Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease. J Huntingtons Dis (2014) 0.76
Effects of lisdexamfetamine and s-citalopram, alone and in combination, on effort-related choice behavior in the rat. Psychopharmacology (Berl) (2015) 0.75
Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects. J Psychiatry Neurosci (2014) 0.75
Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother (2006) 1.45
Cranberry and urinary tract infections. Drugs (2009) 1.26
Contemporary management of uncomplicated urinary tract infections. Drugs (2008) 0.92
Inappropriate sexual behaviors in cognitively impaired older individuals. Am J Geriatr Pharmacother (2008) 0.79